Optipharm.CO.,LTD (KOSDAQ:153710)

Market Cap	71.59B
Revenue (ttm)	20.25B
Net Income (ttm)	-2.66B
Shares Out	14.67M
EPS (ttm)	-181.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	8,214
Average Volume	11,130
Open	4,900.00
Previous Close	4,915.00
Day's Range	4,855.00 - 4,900.00
52-Week Range	4,400.00 - 6,730.00
Beta	0.11
RSI	26.01
Earnings Date	n/a

About Optipharm.CO.,LTD

Optipharm.CO.,LTD operates as a biomedical solution provider in South Korea. It also engages in animal disease diagnosis, animal medicine, bacteriophage, Medipig, xenogenic organs, VLP vaccines, xenotransplantation, and other optipharm products, as well as veterinary drug for feed additives and laboratory animal Medipig business. The company was formerly known as Optiparm Solution Co., Ltd. and changed its name to Optipharm.CO.,LTD in 2012. Optipharm.CO.,LTD was founded in 2000 and is based in Cheongju, South Korea.

• Industry: Pharmaceutical Preparations
• Founded: 2000
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 153710

Financial Performance

In 2024, Optipharm.CO.,LTD's revenue was 19.64 billion, an increase of 13.03% compared to the previous year's 17.37 billion. Losses were -2.36 billion, -3.29% less than in 2023.